HIV patients with a CD4+ count below 200 should be treated to prevent the development of Pneumocystis jiroveci pneumonia (PCP). The proper prophylaxis for this is TMP-SMX.
TMP-SMX (trimethoprim-sulfamethoxazole) is a combination drug used to help with prophylactic coverage in HIV patients. It is used in patients with CD4+ counts below 200 to prevent Pneumocystis jiroveci pneumonia (PCP), and in patients with CD4+ counts below 100 to prevent toxoplasmosis.
Pneumocystis jiroveci pneumonia (PCP) is an opportunistic infection which affects HIV patients with CD4+ counts below 200.
At CD4+ counts below 100, patients are susceptible to opportunistic infection by Toxoplasma gondii. Thus, when a patient's CD4+ count drops below 100, they are prophylactically given TMP-SMX.
Severely immunocompromised patients with a CD4+ level of below 50 are susceptible to infections with Mycobacterium avium complex (MAC). Routine prophylaxis against MAC is no longer recommended, however.
Mycobacterium avium, or MAC, refers to a group of different Mycobacterium species which can all cause similar infections in AIDS patients. Two of the most common organisms are M. avium and M. intracellulare. Clinical manifestations include fever, weight loss, and night sweats in patients with CD4+ counts below 50. Routine prophylaxis is not recommended, but disseminated disease confirmed by blood culture positivity can be treated with azithromycin and ethambutol.
Routine prophylaxis against MAC is no longer recommended for patients with a CD4+ count below 50, as long as the patient recently began antiretroviral therapy for AIDS. This is because the risk of MAC infection is low in patients who are on therapy. However, if antiretroviral therapy is delayed for any reason, then prophylaxis with azithromycin is recommended until the patient begins therapy.
Picmonic's rapid review multiple-choice quiz allows you to assess your knowledge.
*Average video play time: 2-3 minutes
Unforgettable characters with concise but impactful videos (2-4 min each)